LVTX vs. CNTX, GRFS, MYNZ, NLSP, PHVS, TLSA, ATNFW, SXTPW, ACONW, and AIMDW
Should you be buying LAVA Therapeutics stock or one of its competitors? The main competitors of LAVA Therapeutics include Context Therapeutics (CNTX), Grifols (GRFS), Mainz Biomed (MYNZ), NLS Pharmaceutics (NLSP), Pharvaris (PHVS), Tiziana Life Sciences (TLSA), 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Aclarion (ACONW), and Ainos (AIMDW). These companies are all part of the "medical" sector.
LAVA Therapeutics (NASDAQ:LVTX) and Context Therapeutics (NASDAQ:CNTX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation, community ranking and media sentiment.
Context Therapeutics has a net margin of 0.00% compared to LAVA Therapeutics' net margin of -620.09%. LAVA Therapeutics' return on equity of -68.54% beat Context Therapeutics' return on equity.
In the previous week, Context Therapeutics had 5 more articles in the media than LAVA Therapeutics. MarketBeat recorded 8 mentions for Context Therapeutics and 3 mentions for LAVA Therapeutics. Context Therapeutics' average media sentiment score of 0.92 beat LAVA Therapeutics' score of 0.72 indicating that Context Therapeutics is being referred to more favorably in the news media.
Context Therapeutics has lower revenue, but higher earnings than LAVA Therapeutics. LAVA Therapeutics is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.
LAVA Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 2.14, meaning that its stock price is 114% more volatile than the S&P 500.
LAVA Therapeutics received 10 more outperform votes than Context Therapeutics when rated by MarketBeat users. Likewise, 75.86% of users gave LAVA Therapeutics an outperform vote while only 63.16% of users gave Context Therapeutics an outperform vote.
14.0% of Context Therapeutics shares are held by institutional investors. 0.8% of LAVA Therapeutics shares are held by insiders. Comparatively, 6.7% of Context Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
LAVA Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 94.17%. Context Therapeutics has a consensus price target of $7.50, suggesting a potential upside of 301.07%. Given Context Therapeutics' higher possible upside, analysts plainly believe Context Therapeutics is more favorable than LAVA Therapeutics.
Summary
Context Therapeutics beats LAVA Therapeutics on 10 of the 15 factors compared between the two stocks.
Get LAVA Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LVTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
LAVA Therapeutics Competitors List
Related Companies and Tools